Administering the HPV Vaccine to People Living with HIV: Providers' Perspectives
AffiliationUniv Arizona, Mel & Enid Zuckerman Coll Publ Hlth
Human papillomavirus (HPV)
MetadataShow full item record
CitationKoskan, A., Brennhofer, S.A. & Helitzer, D. Administering the HPV Vaccine to People Living with HIV: Providers’ Perspectives. J Primary Prevent 41, 349–362 (2020). https://doi.org/10.1007/s10935-020-00598-w
JournalJOURNAL OF PRIMARY PREVENTION
Rights© Springer Science+Business Media, LLC, part of Springer Nature 2020
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractHIV-positive patients suffer disproportionate burden of anal cancer, a disease which is primarily caused by persistent infection with human papillomavirus (HPV) and is potentially preventable with the completion of the HPV vaccine series. Past research qualitatively explored HIV-positive patients' perspectives about the HPV vaccine. However, little is known about their healthcare practitioners' vaccine recommendation behaviors, the strongest influence on vaccine uptake. This study reports on in-depth interviews conducted with 25 healthcare practitioners who provide care for HIV-positive patients. Qualitative themes that emerged from the study included clinicians' HPV vaccination behaviors, HIV patient's willingness to get the HPV vaccine, the role of HIV-positive patients' immune functioning in terms of timing of HPV vaccine administration, and vaccinating HIV-positive patients over age 26. The majority of providers offered the vaccine at their healthcare facility. Participants varied in their opinions related to the importance of patients' CD4 count in terms of timing of HPV vaccine administration; some believed that patients' immune functioning should first be stabilized to receive the most benefit from the vaccine series. They also differed in the perceived benefit of offering the vaccine to patients over age 26. In light of the U.S. Food and Drug Administration's recent approval to extend HPV vaccination to adults up to age 45 years, more HIV-positive adults may benefit by receiving this vaccine series. Future efforts should ensure that providers regularly promote the HPV vaccine to their adult HIV-positive patients. Vaccinating HIV-positive patients may help reduce the burden of HPV-related cancers, particularly anal cancer.
Note12 month embargo; published online: 1 July 2020
VersionFinal accepted manuscript
- HPV-Related Cancer Prevention and Control Programs at Community-Based HIV/AIDS Service Organizations: Implications for Future Engagement.
- Authors: Wigfall LT, Bynum SA, Brandt HM, Sebastian N, Ory MG
- Issue date: 2018
- HIV-positive gay men's knowledge and perceptions of Human Papillomavirus (HPV) and HPV vaccination: A qualitative study.
- Authors: Grace D, Gaspar M, Paquette R, Rosenes R, Burchell AN, Grennan T, Salit IE
- Issue date: 2018
- Economic barriers, evidentiary gaps, and ethical conundrums: a qualitative study of physicians' challenges recommending HPV vaccination to older gay, bisexual, and other men who have sex with men.
- Authors: Grace D, Gaspar M, Rosenes R, Grewal R, Burchell AN, Grennan T, Salit IE
- Issue date: 2019 Oct 17
- A model of health care provider decision making about HPV vaccination in adolescent males.
- Authors: Alexander AB, Best C, Stupiansky N, Zimet GD
- Issue date: 2015 Aug 7
- Providers' beliefs about the effectiveness of the HPV vaccine in preventing cancer and their recommended age groups for vaccination: Findings from a provider survey, 2012.
- Authors: Berkowitz Z, Malone M, Rodriguez J, Saraiya M
- Issue date: 2015 Dec